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DNA block copolymersThe ﬁeld of DNA nanotechnology has progressed rapidly in recent years and hence a large variety of 1D-, 2D-
and 3D DNA nanostructures with various sizes, geometries and shapes is readily accessible. DNA-based
nanoobjects are fabricated by straight forward design and self-assembly processes allowing the exact posi-
tioning of functional moieties and the integration of other materials. At the same time some of these
nanosystems are characterized by a low toxicity proﬁle. As a consequence, the use of these architectures in
a biomedical context has been explored. In this review the progress and possibilities of pristine nucleic
acid nanostructures and DNA hybrid materials for drug delivery will be discussed. For the latter class of struc-
tures, a distinction is made between carriers with an inorganic core composed of gold or silica and amphiphil-
ic DNA block copolymers that exhibit a soft hydrophobic interior.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Since the discovery of the DNA double helix structure in 1953many
researchers have been intrigued not only by its role and the processes
involved in storing genetic information but also by its utilization as a
building block for nanostructures [1]. This trend has been fuelled by
the introduction of automated solid phase synthesis, polymerase
chain reaction and molecular cloning techniques allowing to produce
oligonucleotides (ODNs) and long nucleic acid strands and make them
available for awide scientiﬁc community at an affordable price or effort.
The versatile fabrication methods and the notion about the position of
each atom within double-stranded (ds) DNA in combination with the
unique self-recognition properties of DNA have made nucleic acids
one of the most popular construction materials for nano-scale objects
(Fig. 1) [2]. Early models of DNA self-assembly relied on the hybridiza-
tion of single-stranded (ss) ODNs into double strands to form nucleic
acid junctions [3,4]. Each junction is composed of four DNA sequences
and contains short ss overhangs called “sticky ends” (Fig. 2A). These
units provide a toehold for controlled assembly of multiple junctions,
thereby creating a lattice of squares. In a similar way a cube can be
formed by catenating six circular DNA strands mediated by hybridiza-
tion and ligation (Fig. 2B) [5].
However, these assembly processes did not yield rigid junctions
with deﬁned angles and hence the geometry of the resulting struc-
tures was not well deﬁned. To overcome these shortcomings two
methods were developed to obtain well deﬁned and structurally sta-
ble DNA nanoobjects. The ﬁrst one involves DNA tiles that utilize the
helical turn of DNA to form crossovers between two or more doublerights reserved.strands within its structure (Fig. 3A). This design principle yields
more rigid building blocks of high structural integrity that can be
used for the construction of larger crystals of DNA [6,7]. Later this
method was greatly expanded and generalized to allow the assembly
of DNA into any desired shape like squares, triangles, star shapes or
even smilies using a single viral DNA strand and many short ones
that function as connecting elements, the “staple strands” [8]. An ex-
ample of a 3D structure is a DNA box that contains a controllable lid
(Fig. 1A) [9]. To date these DNA origami structures can be easily
designed and synthesized and are applied for detection of biomole-
cules like proteins or DNA and for performing reactions at the nano-
meter scale [10–12].
The second method to obtain rigid DNA nanoobjects relies on the
tensegrity principle (Fig. 3B) [13,14]. The squares considered earlier
were unstable due to ﬂexible junctions. DNA triangles, however, do
not face this shortcoming and when the edges are composed of this
motif rigid structures are obtained [15]. Therefore, many researchers
have used this principle to construct a large number of DNA nanocages
resistant to deformation like tetrahedra, octahedra, dodecahedra and
icosahedra [16–20].
Aside from using pristine DNA as building block inorganic
nanoparticles (NPs) have been used as template for the organization
of ODNs. One very appealing template for this purpose is colloidal
gold that was ﬁrst used in 1996 when DNA functionalized gold
nanoparticles (DNA-Au NPs) were introduced [21]. Thiol-terminated
ODNs readily react with the surface of Au NPs and subsequent hybrid-
ization gives access to assemblies of higher order [22,23]. DNA-Au
NPs offer some extra features like magnetic properties, plasmonic ef-
fects or the ability of ﬂuorescence quenching, which represent a sig-
niﬁcant extension to the functionality of pristine DNA nanoobjects








Fig. 1. Different classes of DNAnanostructures including (A) pristineDNAnanoobjects, (B)
inorganic-DNA hybrid materials and C) assemblies of amphiphilic DNA block copolymers.
Reproduced with permission from [9,24].
B
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Fig. 3. Assemblies based on DNA tiles. (A) A 2D-pattern of DNA that is based on four
different tiles named A, B, C and D. The colors at the vertical edges represent overhangs
that hybridize with overhangs of other tiles with the same color (top). Example of a
single DNA tile (bottom). (B) DNA tiles that self-assemble into 3D-nanoobjects.
Reproduced with permission from [6,20].
468 J.W. de Vries et al. / Journal of Controlled Release 172 (2013) 467–483and biomedicine; hence DNA-Au NPs have become a very popular
template for the assembly of nanoobjects and currently ﬁnd use in
imaging, detection and as transfection agents and gene regulation
materials [25–28].
In addition to DNA nanoparticles with an inorganic core such
structures can be produced with a soft interior. The realization of
these structures implies the use of synthetic organic polymers. The
ﬁrst DNA polymer conjugates date back to the late 1980s, where
poly(L-lysine)-block-DNA was used as anti-viral agent [29,30]. Nowa-
days, nucleic acid-polymer hybrid materials are already in clinical use
[31]. Thereby, a hydrophilic synthetic macromolecule component was
connected to an aptamer for increasing the in-vivo stability of the
nucleic acid. For the realization of DNA polymer nanoobjects hydro-
phobic polymers need to be attached to the DNA units to achieve
self-assembly into larger aggregates. The ﬁrst example of such an
amphiphilic biodegradable DNA block copolymer (DBC) contained
poly(D,L-lactic-co-glycolic acid) as a hydrophobic polymer block [32].
These compounds form micellar structures that exhibit a hydrophobic
core and a hydrophilic corona of ss DNA. More recently, several groups
realized such micellar morphologies and in addition showed that
the overall structure can be altered from spherical to cylindrical assem-
blies by stimuli like changes in pH, addition of endonucleases or
through hybridization with complementary DNA [33,34]. Due to these
unique properties, DBCs are currently applied in puriﬁcation of bioma-
terials [35,36], DNA detection [37], templated synthesis [38] and in
nanoelectronics [39].
All classes of DNA nanomaterials described above have in common
that the size and shape are very well deﬁned, probably better than in
any other bottom-up fabricated material. This feature has dramatic
consequences for applications in the ﬁeld of biomedicine where
multifunctional nanoparticles start to play an increasingly important
role, especially in the areas of drug delivery and bioimaging. The
DNA nanoobjects act as a shape persistent scaffold allowing precise
positioning of various moieties like targeting units or drug payloads.BA
Fig. 2. (A) On the left a representation of a nucleic acid junction formed from four ss
DNA sequences is shown and on the right the corresponding lattice formed by hybrid-
ization of the sticky ends is depicted. (B) DNA cube formed by catenated circular DNA
strands.
Reproduced with permission from [4].On the other hand all the different types of DNA assemblies exhibit
distinctive properties. While the functionality of a pristine DNA
scaffold is relatively limited, in the case of DNA hybrid materials
extra functions are implemented via the non-nucleic acid compo-
nents. All these different features will be highlighted in this review
article.
Although the use of DNA nanoobjects in biomedicine is still in its
early stages, promising examples have been provided that demonstrate
the applicability and beneﬁts of using DNA-based nanomaterials over
other systems like liposomes, polymeric micelles and polymersomes
[40–43]. The most obvious use of oligonucleotide nanostructures in
themedical ﬁeld is the delivery of siRNA, antisense RNA or genes. How-
ever, several excellent reviews on this topic have been published re-
cently [44–47]. The same holds true for DNA nanoobjects employed in
the context of cellular and in-vivo bioimaging [48,49]. Therefore, both
topics will not be covered in this manuscript. Here we will summarize
the use of pristine DNA nanoobjects and DNA hybrid materials as car-
riers in the ﬁeld of therapeutic delivery and vaccination. For the dif-
ferent classes of DNA nanomaterials we start with describing the
preparation methods followed by the stability in biological
AB
C D
Fig. 4. (top) Synthetic scheme for a tetrahedron composed of four DNA strands. (bottom)
Schematic design of the DNA tetrahedronwith controllable porosity. (A) Four 3-point-star
tiles are used to construct a DNA tetrahedronwith extended ss tails near themiddle of the
struts, offering the binding sites for the capping motif (CM), which is formed through hy-
bridization of a longer circular DNA strand (CL) with three copies of shorter strands (CS).
CM can be removed by addition of a cap-removal strand (CR) that is fully complementary
to CL. (B) Details of dimer formation between two 3-point-star motifs. (C, D) Face struc-
tures of a uncapped and capped tetrahedron, respectively.
Reproduced with permission from [50,51].
469J.W. de Vries et al. / Journal of Controlled Release 172 (2013) 467–483environments and cell uptake behavior. Finally, we discuss controlled
release or performance of the nanostructures in-vitro and in-vivo.
2. Delivery with pristine DNA scaffolds
2.1. DNA tetrahedra
While the ﬁeld of DNA nanotechnology aimed for increasing the
structural complexity, which is often associated to the utilization of a
large number of DNA strands per nanoobject, the demands for
DNA-based carrier systems pose different requirements on the design.
Since for in-vitro and in-vivo experiments usually larger quantities of
materials are needed, the number of strands per DNA nanostructure
with different sequence composition should be kept at a minimum due
to cost issues. For the same reason the lengths of the sequences should
be limited. One example of such a structure consisting of a small number
of sequences is the DNA tetrahedron [50] and it was even demonstrated
that this nanoobject can be prepared froma single DNA strand of 286 nu-
cleotides (nt) [16]. While this approach requires the synthesis of DNA by
rolling circle ampliﬁcation or in-vivo replication, the same object can be
realized from four chemically synthesized single strands of 55 nt. The
resulting structures exhibit edges being composed of 17 base pairs (bp)
of ds DNA which equals 5.8 nm considering a length of 0.34 nm per bp
(Fig. 4, top) [50]. An object of the same geometry was realized by assem-
bly of DNA tiles [51]. Seven strands were converted into a tile and four of
these units form a tetrahedral structure. At themiddle of each strut of the
tetrahedron one ss overhang was incorporated that allows the imple-
mentation of a triangular feature within each plane of the object (Fig. 4,
bottom). By the addition of interfering strands these inserts can be re-
moved allowing the change of porosity of the tetrahedron's surface,
which might be important for the trapping and release of cargo.
Initial experiments for the cell uptake of a tetrahedral DNA nano-
structure were performed without any cargo [52]. For that purpose cul-
tured human embryonic kidney cells were incubatedwith ﬂuorescently
labeled DNA cages. The uptakewas investigated by confocalmicroscopy
and ﬂow cytometry. Signiﬁcant internalization of the tetrahedron was
detected for pristine nanoobjects and for ones treated with a transfec-
tion reagent. Subcellular localization revealed presence of the cages in
the cytosol. Stability experiments were carried out employing Förster
resonance energy transfer (FRET) experiments indicating structural in-
tegrity of theDNA cages for at least 48 h. The same cageswere equipped
with CpG motifs to induce immunostimulation [53]. CpG motifs are
short oligonucleotides where a 2′-deoxycytidine is connected by a
phosphodiester bond to 2′-deoxyguanosine. When these nucleotides
are unmethylated as in natural viral and bacterial DNA they have
immunostimulatory activity [54]. This CpG motif occurs very rarely in
vertebrate genomes and is therefore considered a pathogen-associated
molecular pattern indicating invasion of pathogens [55]. In this context
the ﬁrst step of eliciting an immune response is binding of CPG ODNs to
Toll-like receptor 9 (TLR9) present in B cells and plasmacytoid dendritic
cells (pDCs), which is followed by a signaling cascade [56]. In a thera-
peutic context, CpG ODNs can be applied as an agonist of TLR9 to
boost the immune response which is favorable during the treatment
of cancer and allergic diseases [57]. For that reason CpG-derived ODNs
were investigated and tested in preclinical studies as vaccine adjuvants
[58,59].
When the CpG motifs were appended to the tetrahedron, the
nanoobjects were resistant to nuclease degradation and remained in-
tact in fetal bovine serum and in cells for at least several hours. More
important, they entered macrophage-like RAW264.7 cells without
transfection agents and their CpG motif was recognized by TLR9. As a
result of that binding event immunoregulatory downstream pathways
were activated (Fig. 5, top). Various pro-inﬂammatory cytokines in-
cluding tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-12
were up-regulated. Due to the fact that the tetrahedral nanostructures
are mechanically stable several CPG motifs attached to the surfaceswere accessible for TLR9 which resulted in a multivalency effect of en-
hanced immunostimulation (Fig. 5, bottom) [60].
After these successful in-vitro experiments DNA tetrahedra equipped
with CpG motifs were employed in-vivo for vaccination (Fig. 6A) [61].
Therefore, streptavidin (STV) was incorporated into the DNA nanocages
to form an antigen–adjuvant complex. The immunogenicity of this
complex was assessed in a BALB/c mouse model by measuring the
anti-STV antibody response and comparing it to an unassembledmixture
of STV and CpG ODN or STV alone. It was found that mice immunized
with the STV-CpG ODN-tetrahedron developed a much higher level of
anti-STV IgGs than the above mentioned controls after a period of
70 days. To substantiate this outcome antibody secreting cells (ASCs)
that originate from STV-speciﬁc memory B cells present in spleen cells
were quantiﬁed (Fig. 6B). Signiﬁcantly elevated levels of speciﬁc ASCs
were determined for mice immunized with the tetrahedron-CpG ODN–
STV complexes compared to those immunized with free CpG + STV
and STV only. These results indicate that the fully loaded tetrahedron in-
duces a strong and long-term immunity against the antigen due in part
AC
B
Fig. 5. (top) Assembly of CpG grafted DNA tetrahedron delivery systems for eliciting an
immune response. (bottom) Release levels of cytokines TNF-α (A), IL-6 (B) and IL-12
(C) from RAW264.7 cells using different immunostimulatory nanoobjects.
Reproduced with permission from [60].
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proved the safety of the DNA carrier because no immune response
against the carrier, i.e. a ds DNA tetrahedron, was developed, which
could result in tissue damage or trigger autoimmunity [61]. This work
shows the great potential of scaffolds generated by DNAnanotechnology
to serve as a general platform for vaccine development. A major part of
the DNA tetrahedron's potency in the biomedical ﬁeld is derived from
its rigid 3D scaffold allowing speciﬁc multivalent interactions with cellu-
lar components.
However, DNA tetrahedra with a ﬂexible unit were generated
as well [62]. One of the struts of the tetrahedron was constructed
from a ss RNA aptamer recognizing ATP. When this assembly was in-
ternalized into HeLa cells ATP levels within living cells could be mea-
sured indicating that the construction of intracellular logic sensors is
feasible.A B
Fig. 6. (A) Schematic drawing of the DNA tetrahedron vaccine complex containing the
antigen streptavidin (red) and CpG ODNs (purple). (B) ELISPOT assay of speciﬁc mem-
ory B cell response in mice stimulated by STV, STV + CpG and CpG-STV DNA tetrahe-
dron, respectively.
Reproduced with permission from [61].2.2. Branched DNA nanostructures and polypods
The DNA tetrahedron represents a simple shape persistent scaffold
allowing to present four units at each vertex like the CpG motif or cell
surface recognizing aptamers. Equally simple regarding the design but
of more structural ﬂexibility are branched structures or polypods. The
simplest assembly of this type is Y-shaped and can be constructed
from three ODN strands (Fig. 7, top) [63]. Already in 2008 such a
DNA nanostructure was equipped with several immunostimulatory
CpG motifs [64]. Cytokine production (TNF-α and IL-6) after addi-
tion of the Y-structure to RAW264.7 cells was measured. It was
found that the ds Y-shape is effective in inducing greater amountsDC
Fig. 7. (top) Schematic representation of Y shaped ODNs. (middle) Schematic design of
dendrimer-like DNA (DL-DNA), from left to right: Y-DNA; ﬁrst generation DL-DNA, sec-
ond generation DL-DNA, and third generation DL-DNA, (bottom) Schematic representa-
tion of models of polypods: (A) tripod-DNA, (B) tetrapod-DNA, (C) hexapod-DNA and
(D) octapod-DNA.
Reproduced with permission from [63,65,66].
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ventional ss or ds ODNs containing the same amounts of CpG motifs.
This high immunostimulatory activity of Y-ODN is at least partly associ-
ated with increased uptake by the TLR9-positive cells but not with sta-
bilization through the DNA nanostructure. Other factors like higher
afﬁnity of Y-ODN to the TLR9 receptor or intracellular localization may
also contribute to the increased immunostimulation.
In a follow up study the same authors fabricated dendritic DNA
nanostructures by ligating Y-shaped DNAmonomers [65]. In this man-
ner, the second and third dendrimer generation were fabricated with
12 and 24 CpG motifs located at the periphery of the DNA nanostruc-
tures, respectively (Fig. 7, middle). The dendritic DNA architectures in-
duced greater amounts of TNF-α and IL-6 from RAW264.7 cells than a
mixture of Y-shaped DNA encoding the same CPG motifs as present in
the dendrimers. The dendritic DNA was internalized six to 15 times
more efﬁciently by the macrophage-like cells than Y-DNA, which
resulted in the secretion of much greater (100-fold or more) amounts
of cytokines. These results suggest that a dendritic architecture with
multiple CpG motifs at the rim is a viable design for a DNA nanostruc-
ture to increase the immunostimulatory activity without any chemical
modiﬁcation of the natural phosphodiester DNA backbone.
In addition to the trigonal Y-shaped unit, polypods with a higher de-
gree of branching were evaluated regarding their immunostimulatory
potential [66]. For that purpose a tri-, tetra-, hexa- and octapod
consisting of three, four, six and eight ODNs, respectively, were assem-
bled (Fig. 7, bottom). Again at the end of the branches CpG motifs were
established yielding assemblies consisting of DNA in the B-form with a
diameter of around 10 nm. The melting temperature of the nanoobjects
decreased with increasing the degree of branching. Each polypod DNA
induced the secretion of TNF-α and IL-6 from macrophage-like
RAW264.7 cells to a greater extent than ss or ds non-branched CpG
containing DNA. Evenly important, the highly branched architectures,
i.e. hexa- and octapod, were more effective in stimulating cytokine pro-
duction than the structures with a lower branching degree, i.e. tri- and
tetrapod. Other properties that are dependent on the degree of
branching are the uptake and the stability in serum. The more branched
the polypods are the better they are taken up in TLR9-positive cells but
the less stable they are. From these results it could be concluded that
the CpG-containing polypods with hexagonal and octagonal symmetry
are promising biodegradable nanoobjects with high immunostimulatory
activity.
2.3. DNA icosahedra
In addition to directly using branched DNA structures for
immunostimulation, more complex polyhedra can be fabricated from
those building blocks. The resulting assemblies contain a triangular
tensegrity motif and were employed for drug delivery purposes [67].
From six individual DNA single strands, six-point-star motifs were
formed (Fig. 8A) that via sticky end cohesion self-assemble into an ico-
sahedron (Fig. 8B). In one of the six strands an aptamer sequence was
incorporated that protrudes from the icosahedron surface and is re-
sponsible for MUC 1 recognition. This protein belongs to an importantA B C
Fig. 8. Schematic representation of (A) the six-point-star motif, (B) the DNA icosahe-
dron and (C) the DNA icosahedron containing intercalated Dox for targeted delivery.
Reproduced with permission from [67].class of tumor surface markers which are uniquely expressed on a
broad range of epithelial cancer cells with high abundance [68,69].
The ﬁnal step of the carrier fabrication consisted of loading of doxorubi-
cin (Dox) by intercalation (Fig. 8C). This anthracycline derivative is fre-
quently employed in chemotherapeutic anticancer treatment [70–72].
The potency of the icosahedral carrier system was assessed by in-vitro
cell culture experiments employing ﬂow cytometry, confocal ﬂuores-
cence microscopy and cytotoxicity tests. In co-culture experiments it
could be demonstrated that the DNA nanocarrier was efﬁciently taken
up by the human breast cancer cell line MCF-7 that is MUC1 positive
while no internalization was observed in Chinese hamster ovary cells
(CHO-K1) that donot expressMUC1. Besides this superb targeting func-
tion the Dox-loaded carrier exhibited a greater cytotoxicity in MCF-7
cells than free Dox indicating speciﬁc and efﬁcient delivery of antican-
cer drugs and suggesting the potential use of DNA icosahedra for use
in targeted cancer therapy [67].
Another function thatwas realizedwith icosahedral DNAnanostruc-
tures is in-vivo imaging [73]. Therefore, ﬂuorescein isothiocyanate
(FITC)-labeled dextran (FD10) with a molecular weight of 10 kDa was
encapsulated in an icosahedral DNA cage. The encapsulation procedure
starts with the formation of two icosahedral halves from ﬁve-way
junctions similar as described above (Fig. 9A) [19]. These two assem-
blies were incubated with FD10 and subsequently joined by hybridiza-
tion resulting in a full DNA icosahedron containing two FD10 units
within their interior (Fig. 9B). These host guest complexes were
microinjected into Caenorhabditis elegans. This organism is a nematode
that contains scavenger cells, called coelomocytes, which endocytose
ﬂuid from the pseudocoleom. After introducing the loaded icosahedra
these nanoobjects were speciﬁcally internalized by the coelomocytes
due to interactions with anionic ligand-binding receptors and subse-
quent receptor-mediated endocytosis. In stark contrast, the pristine
FD10 lacks negative surface charges and was therefore taken up by
ﬂuid phase endocytosis resulting in its non-speciﬁc distribution
throughout the pseudocoleom after microinjection. After proving the
complete alteration of endocytotic uptake pathways due to different
molecular interactions the functionality of the cargo was examinedFig. 9. (A) Synthetic strategy for constructing the DNA icosahedron, (B) encapsulation
of (FITC)-dextran into DNA icosahedron.
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Fig. 10. (A) DNA origami structures used for testing the stability in cell lysate, from left
to right: 2D rectangle, 2D equilateral triangle, 3D multilayer rectangular structure and a
2D rectangle with staple strands bearing ss overhangs. (B) (Left) Schematic represen-
tation of DNA origami structure for nucleic acid detection (Rag-1, C-myc, β-actin and
control). The DNA square was composed of circular single-stranded M13 viral DNA
(black) and >200 staple strands. Through incorporation of helper strands ss overhangs
were formed allowing for hybridization with the target sequence. (Right) 3D illustra-
tion of the DNA origami. (C) Representation of target detection using DNA origami
structures. (D) (Top) ss helper strands on top of the tile and (bottom) detection of tar-
get sequence using atomic force microscopy (AFM).
Reproduced with permission from [77] and [10].
472 J.W. de Vries et al. / Journal of Controlled Release 172 (2013) 467–483in-vivo. Due to their pH sensitivity, FITC on Dextran was employed as
pH sensor to measure the proton concentration in organelles, inside
cells and whole organisms [74,75]. When encapsulated in the DNA
nanocage this function remains unchanged and the host guest com-
plexes were employed to map the pH changes during endosomal mat-
uration along the ALBR pathway in coelomocytes in living worms.
This work represented the ﬁrst demonstration of functionality and
emergent behavior of a cargo-loaded DNA nanostructure in-vivo [73].
2.4. DNA origami
As introduced above, the DNA origami technique deals with fold-
ing a ss long DNA strand into almost any 2D or 3D shape with the
help of many different “staple” strands [8,76]. These strands bind to
the long one at different positions to deﬁne the overall structure
and they can be utilized to site speciﬁcally introduce additional func-
tionalities by hybridization.
Before the DNA origami structures were introduced for biomedical
purposes their stability in cell lysates was investigated [77]. Four assem-
blies were fabricated for that purpose: a 2D rectangular origami
(90 × 60 nm) [10], a 2D equilateral triangle (120 nm long with 30 nm
wide sides) with an open central triangular cavity of 60 nm per side, a
3D multilayer rectangular parallelepiped structure (16 × 16 × 30 nm)
and a 2D rectangular structure with staple strands bearing overhangs
allowing hybridization (Fig. 10A) [10]. These DNA architectures were in-
cubatedwith cell lysate fromwhich nuclear DNA and cell membrane de-
bris were removed. After incubation times of 1 and 12 h the origami
structures were investigated by non-denaturing gel electrophoresis and
by direct visualization employing AFM as well as transmission electron
microscopy. Taking into account all three methods it can be concluded
that all the origami assemblies are stable at 25 °C with the cell lysates
tested, i.e. metaplastic human esophageal epithelial cell line [78], End1/
E6E7 cells, MCF-10A cells and cancerous HeLa and MDA-MB-231 cells.
In contrast, ss M13mp18 viral DNA and ds λ DNA that acted as control
showed alterations already after 1 h incubation with the cell lysates. Fi-
nally, it was demonstrated that ss DNA features protruding from the ori-
gami structures remained intact and could be successfully used for
detection of mRNA from the lysate (Fig. 10B). These results suggest
that DNAorigami scaffolds have the potential to serve as an in-vitro diag-
nostic platform and might be of importance for single cell proteomic
analysis when integrated into microﬂuidic chips.
The same results also conﬁrm the stability of DNA origami objects
inside cellular environments and therefore their application as delivery
vehicle will be discussed in the following paragraph. As shown above
many DNA nanostructures were tested regarding their immuno-
stimulatory potencywhen equippedwith CpGmotifs. For the samepur-
pose structurally complex DNA origami scaffolds were successfully
utilized as well. Freshly isolated spleen cells were incubated with a hol-
low 30-helix origami tube (approximately 80 × 20 nm) with 62 bind-
ing sites for hybridization of CpG motifs distributed over the surface.
This DNA origami scaffold that was constructed from M13mp18 DNA
(8634 nt) and 227 staple ODNs was taken up into endosomes and
triggered a strong immune response indicated by cytokine secretion,
which was entirely dependent on TLR9 stimulation. As controls for
the DNA origami tubes, CpG ODNs complexed with lipofectamine, a
standard transfection agent, were employed which showed lower
immunostimulationwhen applied at equal amounts. Tubeswithout hy-
bridized CpGmotifs induced a low amount of cytokine production that
was not related to TLR9 recognition. In contrast to the cationic carrier
lipofectamine, the DNA tubes exhibited no detectable cytotoxicity for
splenocytes and therefore qualify themselves as an efﬁcient and
non-toxic immunostimulants.
Similar tubes as generated for immunostimulation were harnessed
for cancer therapy [79]. In this study two types of DNA origami tubes
were employed that were smaller than the one applied for immuno-
stimulation. The ﬁrst type exhibited a straight nanotube structureusing a conventional number of 10.5 bases per helical turn to determine
crossover positions between neighboring helices. This S-Nano design
relied on a scaffold strand containing 7560 nt, exhibited a length of
138 nm and a diameter of 13 nm. As a second design, a twisted version
(called T-Nano) with similar dimensions was constructed (Fig. 11). It is
based on an 8634 nt long scaffold and during hybridization of staples
every seventh nt an insertionwas introduced similar as reported before
[80]. The accommodation of 12 bp per turn resulted in a global right
handed twist to partially relief the stress induced by imposing an
BA
Fig. 11. 3Dmodels of (A) straight nanotube (S-Nano), using 10.5 bp per turn twist den-
sity and (B) twisted nanotube (T-Nano), having 12 bp/turn.
Reproduced with permission from [79].
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was loaded into theDNA origami tubes by intercalation. The T-Nano de-
signwas able to accommodate 33%more Dox than the S-Nano structure
although T-Nano contains only 14% more base pairs than the straight
tube. The difference in loading capacity might be explained by the
higher afﬁnity of Dox to the 12 bp/turn helix. After loading, the release
from the tubes was studied. The T-Nano design retains the drug to a
larger extend than S-Nano resulting in a slower release proﬁle. The
release kinetics of T-Nano indicated that 50% of the drug could be
retained formore than several hourswhichwas translated into a higher
toxicity of this system towards three different breast cancer cell lines
(MDA-MB-231, MDA-MB-468 and MCF-7) compared to free Dox. The
S-Nano/Dox system and ds DNA loaded with Dox were less potent in
similar experiments. These ﬁndings and the non-toxic nature of the
T-Nano origami structure itself suggest that twisted DNA origami de-
signs are a suitable delivery platform for targeted cancer therapy.
In a different study it could even been shown that DNA origami
carriers have the potential to overcome drug resistance [81]. A DNA
origami tube and a triangle were loaded with Dox, similar as de-
scribed above, and were administered to drug sensitive (reg) and
drug resistant (res) MCF7 human breast adenocarcinoma cells
(Fig. 12). Free Dox and Dox-loaded origami assemblies were both ac-
tive in killing the reg-MCF7 cell line. In contrast, free Dox and ds DNA
with intercalated Dox moieties were not effective in inducing cell
death in res-MCF7 cells. However, when the same cells were incubat-
ed with the origami structures containing the same amount of Dox as
the above controls cell death was induced. This is a strong hint that
DNA origami structures have the potential to overcome Dox resis-
tance. In the next step the reason for this characteristic of the origami
carrier was investigated. The origins of cultured cancer cells becom-
ing resistant against cytotoxic anticancer drugs can be manifold
[82,83]. One of the most common reasons is decreased drug concen-
trations inside the cells as e.g. induced by efﬂux pumps in the mem-
brane that eject drugs or decrease drug uptake. In this regard, it was
demonstrated that the folded DNA nanostructures increase the up-
take of the anticancer drug in res-MCF7 cells. Another reason for the
development of multidrug resistance is related to intracellular pH,Fig. 12. Schematic representation of DNA origami systems, DNA tube and DNA triangle,
for Dox delivery.
Reproduced with permission from [81].both in the cytoplasm and in acidic organelles [84]. In tumor cells
with a resistant phenotype the anticancer drugs are predominantly
localized in acidic compartments like the lysosomes and are therefore
not able to reach the site of action, i.e. the cytosol or nucleus [85].
Therefore, the co-administration of agents liberating the drugs from
these compartments was carried out allowing redistribution of the
drug to the active sites [86,87]. In this study, it was revealed that
treatment of res-MCF7 cells with Dox-loaded origami objects resulted
in elevated pH indicating the inhibition of acidiﬁcation of lysosomal
compartments. Taken together, overcoming drug resistance by the
origami assemblies can be explained by a combination of two fea-
tures. Firstly, the origami scaffold increases Dox uptake and, secondly,
induces a change of pH in lysosomes leading to a redistribution of the
drug to the target sites.
A more complex vehicle regarding functionality was based on an
origami design consisting of a hexagonal barrel with dimensions of
35 nm × 35 nm × 45 nm (Fig. 13) [88]. This called logic-gated
nanorobot was constructed in such a way that the two domains
forming the barrel were covalently connected at the rear and were
non-covalently fastened twice at the opposite site. These two
non-covalent connections were designed as DNA aptamer-based
locks that open in response to antigen keys. In the closed state the
lock consists of an aptamer–complement duplex that after binding
of the molecular “key” dissociates or opens to form an aptamer–target
complex. Due to the presence of two aptamer locks at the front side a
logic gate-type behavior can be implemented into the origami struc-
ture. When the locks are equipped with sequences recognizing differ-
ent targets opening of the barrel only occurs when both antigen keys
are present emulating an AND-gate behavior. Inside the DNA barrel
12 attachment sites were placed for the incorporation of cargo mole-
cules by hybridization. Au nanoparticles and Fab antibody fragments
covalently connected to ODNs served as payload. After locking and
loading the functionality of the nanorobot was tested. It was demon-
strated that when the proper combination of antigen keys was
present the nanorobot opens its barrel structure and binds to a cell
surface which was measured by ﬂow cytometry due to the presence
of a ﬂuorescent label that was attached to the payload antibodies. Fi-
nally, the nanorobots were investigated in regard to their ability to
get activated and interfaced to cells to interfere with signaling path-
ways. Thereby it was demonstrated that after speciﬁc unlocking the
nanorobots induced growth arrest in leukemic cells in a doseB
Fig. 13. (A) Schematic front orthographic view of DNA nanorobot in the closed state
with a protein payload attached inside. (B) 3D view of DNA nanorobot in the open state.
Reproduced with permission from [88].
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methods of signaling pathway activation were demonstrated. It was
shown that nanorobots could collect ﬂagellin from solution and in-
duce T cell activation. All the experiments prove that the origami ro-
bots can induce a variety of tunable changes in cell behavior.
Moreover, bioactive molecules may be introduced indirectly via inter-
actions with loaded antibody fragments, enabling applications in
which the robot fulﬁlls a scavenging task before targeted payload
delivery.
While all the origami structures in this paragraph consist of many
different units, especially a high number of staple strands, efforts to re-
duce the quantity of building blocks are necessary for costs efﬁciency
and practical applications. One such alternative to the origami method
to produce tube structures is the utilization of rolling circle ampliﬁca-
tion (RCA). RCA is an enzymatic method that allows the fabrication of
long, ss DNA of periodic sequence from cyclic templates. The resulting
RCA products were employed to construct long tracks of proteins [89]
and nanoparticles [90]. For the assembly of nanotubes, a circular ss
DNA was combined with a primer strand and DNA polymerase Phi29
producing the periodic ss DNA Guide (Fig. 14) [91]. This long DNA
strand coding alternatingly binding regions (BR) and spacer regions
(SR) was hybridized with spacer strand 1a to form 1. The ss BR was
then hybridized with triangular rung 2 to result in an open nanotube
RCA-NTo. This extended structure was transformed in the closed tube
RCA-NT. The dimensions of such triangular tubes could be controlled
by the length of the RCA product ranging from around 0.7 to 1.2 μm.
Similar as the origami tubes, the RCA-derived assemblies were more
resistant towards the digest by nucleases compared to conventional
ds DNA and they were internalized in human cervical cancer cells
(HeLa). With the same cell line, uptake of ds DNA was negligible. Com-
bined with their proven uptake and release behavior these DNA-
economic nanotubes are a potentially unique platform for drug delivery
and bioimaging [92].
An even more reductionist approach regarding sequence efﬁciency
is the use of a single DNA strand that governs the ability to self-
assemble into a tube [93]. This 52 nt long strand is divided into four seg-
ments which exhibit a length of 10, 16, 16 and 10 bases, respectively,
and are all self-complementary. Due to that particular design they as-
semble into tubes with a length of up to 60 μm and varying diameters
in the range of several tenths of nanometers. Initial steps towards
employing these DNA tubes for targeted cancer therapy have been












Fig. 14. Design of RCA nanotubes. The backbone strand 1 with alternating segments of
BR and SR is prepared by RCA. On each vertex of triangular rung 2, two well oriented ss
DNA sequences extend longitudinally for hybridization with 1 to construct the open
nanotube RCA-NTo. Double-stranded linkers 3 and 4 are used to form the full nanotube
RCA-NT.
Reproduced with permission from [91].targeting unit, and Cy3, a ﬂuorescence imaging agent. Subsequently,
cancerous KB cells that overexpress the folate receptor were incubated
with the dually labeled nanotubes. The 1D nanostructures were strong-
ly adsorbed on the cell surface and parts of them effectively internal-
ized. At the same time, like for other DNA tube constructs, they
showed no obvious toxicity.
3. Delivery with scaffolds consisting of nucleic acids combined
with other materials
There are several differences between the DNA nanostructures de-
scribed above and the hybrid materials discussed in this paragraph.
The dominant motif in all pristine nucleic acid assemblies is the
DNA double helix forming a rigid and to a great extent shape persis-
tent scaffold. In DNA nanostructures derived from DNA hybrid mate-
rials both single- and double-stranded nucleic acids are found. In
those materials the orientation of the DNA is dictated by the attach-
ment to the core not by hybridization. While pristine DNA assemblies
almost exclusively rely on Watson–Crick base pairing, nanostructures
from DNA hybrid materials are formed by covalent bonds either to an
inorganic core or to a hydrophobic polymer. Various core structures
are known that served as anchoring points like Au [94], Ag [95],
Fe3O4 [96], CdSe [97], or hydrophobic polymers [98–100].
3.1. DNA nanoparticles with an inorganic core
3.1.1. DNA-Au NPs
The most important inorganic core material in the context of
drug delivery is Au. DNA-Au NPs were fabricated by mixing ODNs
containing a terminal sulfhydryl group with citrate-stabilized colloi-
dal Au NPs. The ODNs replace the small ligand and cover the surface
[21]. To increase the density of DNA a method called salt-aging was
developed. High salt concentrations (>0.15 M) were applied to
screen the negative charges of the DNA backbone allowing the assem-
bly of a densely packed ODN corona [101]. Via these methods DNA
NPs are accessible with core diameters ranging from 2 to 250 nm
[102,103]. Important in the context of biomedical applications and
the long-term toxicity of inorganic NPs [104–106] is the fact that
the Au core can also be completely removed. For that purpose the
ODN was attached via a propargyl ether-modiﬁed terminal nucleo-
tide on an Au NP template and cross-linked. Finally, the core was re-
moved by oxidative dissolution [107].
As for the pristine DNA nanoobjects a major threat for the in-vitro
and in-vivo applications of Au NPs is the digestion by nucleases. De-
tailed studies have been performed for these materials and the ﬁnd-
ings might be of importance for the pristine DNA assemblies as well.
By incubation of DNA-Au NPs with DNAse I it was demonstrated
that ds nucleic acids are more stable when bound to a core compared
to pristine ds DNA [27]. The same stability was observed in an intra-
cellular environment (C166 cells). The reason for the enhanced integ-
rity of DNA bound to the Au NPs was investigated [108]. It turned out
that not steric inhibition of binding of the nuclease was responsible
for the increased stability but the high local ion concentration associ-
ated to the densely packed DNA. Pristine DNA and DNA-Au NPs
exhibited comparable enzymatic digestion rates under conditions
where salt concentrations do not affect the enzyme's activity. In con-
trast, at high salinities the degradation rate of NP-bound DNA was
drastically reduced relative to unbound one. From these results it
was concluded that the high local sodium ion concentration is the
dominating factor for the origin of enhanced stability of DNA. In
serum the stabilizing effect is further increased due to absorption of
serum proteins on the surface of DNA-Au NPs and associated there-
with the reduced access by nucleases.
Even more surprising than the improved integrity of DNA on the
NPs was the ﬁnding that DNA-Au NPs were able to enter a large vari-
ety of cell types. Usually, transfection reagents [109,110] are required
Capture ONT




Fig. 15. Schematic representation of the assembly of targeting Dox-loaded Au NPs
using the PSMA aptamer.
Reproduced with permission from [127].
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negatively charged and represents a strong barrier for the negatively
charged polyelectrolyte DNA due to electrostatic repulsion. Up to now
it was shown that DNA-Au NPs are taken up by more than 30 cell
lines, primary cells and neurons without the need for a positively
charged transfection agent [94]. In view of these remarkable results
with uptake of millions of NPs per cell the mechanism of this process
was studied in more detail. A key requirement for pronounced uptake
is a dense DNA surface layer on the particles since cellular internaliza-
tion of bare citrate particles or particles passivated with BSA is orders
of magnitude lower [111,112]. The inﬂuence of the core for uptake is
minor since bothDNA-coated iron oxide NPs aswell as spherical nucleic
acids (DNA NPs after core removal) exhibit high cellular uptake. The
universal uptake behavior is promoted in part by membrane-bound
scavenger receptors [113] which recognize speciﬁc polyanionic ligands
including ODNs [114] or phosphorthioated ODNs [115] and induce
receptor-mediated endocytosis. A possible uptake mechanism may
look like that: First, serum proteins such as BSA adsorb to the ODN
shell of the Au NPs which slightly inhibits uptake. Subsequently, the
scavenger receptors bind to the DNA-Au NPs and initiate endocytosis
while the serum proteins are replaced from the NP surface. A strong
hint supporting thismechanism is the reduced uptake after these recep-
tors were inhibited by their natural agonists such as poly-inosine and
fucoidan [116].
Due to this favorable property proﬁle, DNA-Au NPs were exploited
for drug delivery purposes. In this context their ability for targeting
was assessed ﬁrst [117]. Therefore, a monoclonal antibody (mAb) rec-
ognizing human epithelium growth factor receptor 2 (HER2) was
conjugated to an ODN. HER2 is part of the ErbB protein family that
is involved in signaling pathways leading to increased cell proliferation
and differentiation [118,119]. The mAb conjugate was hybridized with
DNA-Au NPs to be connected via non-covalent bonds. The resulting
DNA-Au NPs were taken up by HER2-positive cells (SKOV-3) to a
much greater extent and at a faster initial rate relative to HER2-
negative cells documenting the targeting effect and cell type selectivity
of the conjugated mAb.
Besides equipping the DNA-Au NPs with Ab they were loaded with
anticancer drugs [120]. As a starting point served DNA-Au NPs that
were functionalized with an ODN carrying a terminal amine at the
rim of the NP. This terminal group was functionalized with a Pt(IV)
complex. Cisplatin is a well-established anticancer drug [121,122]
and Pt (IV) complexes act as an attractive alternative to Pt (II) species.
Pt(IV) compounds are more inert and cause less side effects relative
to Pt(II)-based anticancer drugs that exhibit higher reactivity and
thus lower biological stability. The Pt(IV)-loaded DNA-Au NPs were
successfully internalized by cells and reduced to liberate cisplatin.
This active species entered the cell nucleus and formed 1,2-d(GpG)
intrastrand cross-links with genomic DNA. The effectiveness of the
Pt DNA-Au NPs was superior to cisplatin in killing several kinds of
cancerous cell lines. Another anticancer drug, paclitaxel, was incorpo-
rated into DNA-Au NPs [123]. This potent chemotherapeutic agent is
characterized by a low solubility in aqueous media which can limit
its effectiveness. Moreover, treatment regimens with this drug were
limited by eventual acquirement of resistance of the cancer cells.
Similar as described in the context of the Pt-loaded NPs, paclitaxel
was covalently connected to the surface of DNA-Au NPs. Through the
conjugation to NPs the hydrophylicity and stability of the drug was sig-
niﬁcantly increased compared to free paclitaxel. The NP-based drug de-
livery system was more effective in inducing apoptosis in-vitro across
several cell lines and concentrations than the free active. Notably, cell
death was even induced in paclitaxel-resistant MES-SA/Dx5 cells
underlining the potency of DNA-Au NP systems for drug delivery.
Besides loading anticancer drugs by covalent connections to the
DNA-Au NPs the chemotherapeutic agents were introduced by
non-covalent bonds into the NP system [124]. Dox and actinomycin
D (actD) were intercalated in pre-designed binding sites of tworespective types of ds DNA-Au NPs (core diameter 15 nm)
[125,126]. Regarding the liberation of the drugs from the carrier it
was found for Dox that the rate constant for release was four orders
of magnitude smaller than for Dox-loaded duplex DNA in solution.
In stark contrast, for actD a similar rate constant for release was
found for NP-loaded drug and drug bound to ds DNA. Cytotoxicity
measurements employing neuroblastoma cells revealed no obvious
toxicity of the unloaded DNA carriers. When loaded with the chemo-
therapeutic agents both vehicles showed higher toxicity at low drug
concentrations but were less cytotoxic at higher concentrations com-
pared to the freely administered actives.
In extension to intercalating Dox molecules into the nucleic acid
shell of Au NPs, the carriers were equipped with a targeting function
[127]. For that purpose served an aptamer that targets prostate cancer
cells by recognizing prostate-speciﬁc membrane antigen (PSMA) (Fig.
15) [128]. The targeted nucleic acid NPs were internalized in LNCaP
cells that express PSMA three times more than PC3 cells that are
PSMA-negative. In addition to histological detection of NP uptake
and quantiﬁcation by inductively coupled plasma atomic emission
spectroscopy, computed tomography was carried out in-vitro to
prove the targeting of the NP system. At the same time these experi-
ments document the utility of this delivery vehicle to fulﬁll also a
bioimaging function.
Besides employing the gold core for imaging purposes, it was
exploited for the stimulus-induced release of anticancer drugs [129].
The shape of the core was chosen to be rod-like (50 nm × 10 nm).
The DNA shell on top was loaded with Dox and the surface was dec-
orated with folic acid targeting units by hybridization. The modular
assembly of this multifunctional carrier is illustrated in Fig. 16. Com-
pared to spherical Au NPs their rod-like counterparts exhibit a
plasmon band at higher wavelength in the near infrared (NIR) region
(650–900 nm). Since NIR light can deeply penetrate tissue [130] and
can be effectively converted into heat after absorption by the Au
nanorods (NRs), the light-induced liberation of Dox from the DNA
coated rods was successfully realized in-vitro and in-vivo. Due to
the drug release, tumor growth in BALB/c nude mice was efﬁciently
inhibited. This work represents an example of a combination of three
kinds of therapy, i.e. NIR-based thermotherapy, triggered chemothera-
py and targeted delivery. Although the NRs were intratumorally
injected this work is the basis for further developments achieving opti-
mal biodistribution for systematic administration. Such an optimization
process is greatly facilitated by the modular assembly platform which
might be easily transferred to treatments of other human diseases.
Fig. 16. Schematic representation of Au NRs for targeted Dox delivery functionalized
using folic acid targeting strands. Upon irradiation with NIR light the NR is heated
and induces dehybridization of the targeting and capture strand, resulting in release
of the loaded drug.
Reproduced with permission from [129].
A
B
Fig. 17. (A) MSN loaded with dye and capped using ds DNA. These architectures can be
employed for delivery employing temperature (left) or enzyme induced (right) re-
lease. (B) A similar approach for capping MSN that uses modiﬁed ODNs. Upon irradia-
tion with UV light the azobenzene modiﬁcation undergoes a conformational change
thereby interfering with hybridization.
Reproduced with permission from [140,141].
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were employed for immunostimulation as well [131]. For that pur-
pose the inorganic core was functionalized with CpG motifs. Striking-
ly, the CpG Au NPs were more than one order of magnitude more
effective in inducing TNF-α secretion compared to naked ss CpG
ODNs. These experiments suggested that CpG Au NPs can act as
proinﬂammatory stimuli in-vitro and might be a promising therapeu-
tic tool in animals.
3.1.2. NPs composed of silica and DNA
Aside from DNA-Au nanomaterials, mesoporous silica nanoparticle
(MSN) conjugates offer great opportunities for drug delivery. These
structures are highly porous and thus have a high drug loading capac-
ity. Furthermore, their pore size can be easily tailored, they are biocom-
patible and exhibit high thermal stability. The synthesis of MSNs
proceeds through growth of triethyl orthosilicate under basic condi-
tions onto micellar rod scaffolds that act as a template and typically
are made of n-cetyltrimethylammonium bromide (CTAB) [132]. After-
wards the surfactant is removed under acidic conditions to yield MSNs
with a diameter of around 100–200 nm and pores with sizes of 2–
10 nm. Functionalized MSNs can be prepared through co-condensation
with functional oligosilicates such as chlorinated or amino-modiﬁed
trimethoxysilanes [133,134]. Herein the position of the functional
group is controlled by the time point at which the modiﬁers are added.
When supplementing them early in the growth process functionalities
will be incorporated in the core, whereas addition at the end of the syn-
thesis yields surface-modiﬁed MSNs.
Due to their channel architecture various types of release mecha-
nisms for MSNs were developed. Most of these mechanisms rely on
external stimuli to trigger the liberation of drugs like the presence
of small molecules [135] or enzymes [136], changes in the redox po-
tential [137] or pH [138] and photoirradiation [139]. A key role in the
release process play different kinds of capping agents that include
organic molecules, gold nanoparticles, polymers, antibodies and
DNA. When using ODNs as gate of the channels, the most straight-
forward method to block the pores is by functionalization of MSNs
with two complementary strands of ss DNA at the pore mouths. Hy-
bridization results in ds DNA that effectively closes the pores and
yields a nanocontainer that is responsive to both temperature
changes and presence of nuclease (Fig. 17A). This simple approach
was successfully used for the delivery of the hydrophobic anticancer
drug camptothecin to human liver cancer cells (HepG2) and showed
improved drug uptake over the free drug while the MSN itself showed
no cytotoxicity [140].
When using modiﬁed ODNs as capping moieties other stimuli
could be employed to release payloads. One such example is thephoto-induced release of Dox that was achieved through incorporation
of photoswitchable azobenzenes in the capping DNA (Fig. 17B) [141]. In
the absence of light these moieties are in a trans-conﬁguration and
therefore allow for hybridization of two DNA strands. However, under
irradiation with UV light the azobenzene undergoes isomerization
into the cis-conﬁguration, which interferes with hybridization. As a re-
sult, the two DNA strands separate and Dox was released. This process
is reversible. Upon irradiation with visible light the pores of the MSN
were closed again after sufﬁcient drug had been released. In-vitro stud-
ies using this method were performed on CEM and A549 cells and re-
vealed that these MSNs do not exhibit obvious cytotoxicity before
irradiation with UV light. However, after irradiation cell viability
dropped to only 10% showing an efﬁcient drug release.
In an approach that used a more complex nucleic acid architec-
ture, the DNA i-motif was employed to facilitate pH responsive re-
lease of a model compound (Fig. 18A) [142]. This special secondary
structure of DNA is comprised of a single strand that folds into a
quadruplex through multiple cytidines that are protonated at acidic
pH [143,144]. In the quadruplex state the pores of the MSN were
blocked. However, at basic pH the cytidines were deprotonated and
the secondary structure was lost within minutes to facilitate release
of the payload. By fabrication of NHS-activated MSNs the ss DNA cod-
ing for the i-motif was coupled to the nanoparticles. After loading of
the DNA-functionalized MSNs with the model compound rhodamine
B, the pH was lowered in order to close the pores. Using this simple
preparation procedure loadedMSNs were obtained that showed com-
plete release of the dye at basic pH within 24 h while less than 5%
leakage was observed in the same period at acidic pH. Furthermore,
AB
Fig. 18. (A) Loaded MSN capped with i-motif DNA. Increase of the pH results in disaggre-
gation of the quadruplex and opening of the pores. (B)Malachite green carbinol-modiﬁed
MSN for light-induced pH increase and dye release.
Reproduced with permission from [142,145].
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amount of payload was liberated.
Besides utilizing changes in pH as stimulus for release, light-
triggered liberation of the loaded compound was achieved using the
i-motif again (Fig. 18B) [145]. For this purpose malachite green carbi-
nol (MGCB) was immobilized on the surface of the NP after introduc-
ing the i-motif. MGCB functions as a light inducible hydroxide emitter
as it dissociates into malachite green cations and OH− upon irradia-
tion with UV light (365 nm). The photochemical transformation cre-
ates a local increase in pH and hence induces the unfolding of the
i-motif and subsequent release of the cargo. When the light is turned
off, the process is reversed and the stable quadruplex is formed
again to close the pores of the MSNs. Using this approach a controlled
pH increase from 4.9 to 10.1 was achieved when irradiating the
nanocarriers. Upon removal of the light source the initial pH value
was regained after 20 min. The release of the loaded model com-
pound (Ru(bipy)32+) proved to be strongly dependent on the light
conditions. Under light irradiation as much as 85% of the payload
was released while in the dark only 5% leakage was observed. In addi-
tion, this approach allowed partial drug release by removing the light
source after the desired amount of cargo was released.
Other DNA structures functioning as gate keepers were realized as
well. To this end metal ion binding stem loop sequences were formed
through hybridization to DNA functionalized MSNs allowing for Zn2+and Mg2+ mediated release of model compounds methylene blue
(MB2+) and thionine (Th+) [146]. Addition of the metal ions resulted
in the formation of a catalytically active complex, called DNAzyme,
that cleaves one of the strands and thereby opens the pores. Using
different DNAzymes metal speciﬁc release was achieved and in a mix-
ture of NPs controlled liberation of payloads was demonstrated. Addi-
tionally, incorporation of an aptamer in the loop sequence resulted in
cappedMSNs requiring two promoters to trigger release. Most impor-
tantly, release of the more relevant DOX was shown employing a
Mg2+ and ATP dependent DNAzyme. As cancerous cells have a high
metabolic activity, large amounts of ATP are present rendering this
approach promising for future tumor treatment.
Apart from using the structural properties of DNA to cap the pores
of MSNs, ODNs were used as anchor to attach different capping
groups by employing the unique self-recognition properties of DNA.
It was shown that avidin was able to function as capping agent
when MSNs were functionalized with biotin modiﬁed ds DNA at the
pore mouths [147]. Upon heating above the melting temperature
the double strands dehybridize and avidin is removed, resulting in re-
lease of the loaded compound from the MSN. Furthermore, it was
shown that the release temperature can easily be altered by changing
the length of the connecting DNA. Aside from heating the whole sam-
ple, release by localized heating was also demonstrated. To this end,
superparamagnetic iron oxide nanocrystals were employed that can
be heated by a rapidly alternating magnetic ﬁeld [148]. Hybridization
of DNA functionalized MSNs with iron oxide NPs that are equipped
with the complementary sequence results in loaded nanoparticles
capped by DNA anchored iron oxide NPs. Additionally, the iron
oxide nanoparticles do not only serve as capping agents, but also
can be employed as contrast enhancing agents in magnetic resonance
imaging. Important to note is that this method provides an elegant
manner for liberation without the need of an invasive stimulus.3.2. Amphiphilic DNA block copolymers
In addition to DNA NPs with an inorganic core, nanosized objects
with a DNA corona and a soft interior part can be generated by
employing polymeric materials. In general, amphiphilic block copoly-
mers have been utilized frequently for drug delivery purposes [149].
Thereby, a hydrophobic polymer segment is covalently connected to
a hydrophilic one. Upon microphase separation, mostly spherical ag-
gregates are formed that exhibit a hydrophobic interior and a hydro-
philic shell [150]. The core is usually exploited to load hydrophobic
drugs or for encapsulation of toxic actives to prevent them from
harming healthy tissue. The shell is often composed of polyethylene
glycol because of its resistance towards protein adsorption and the
prevention of immunogenicity [151]. Alternatively, stimulus respon-
sive water soluble polymer segments are found in the corona of the
micelles allowing the particles to react towards changes in their envi-
ronment to improve the performance of the carrier system.
Another way to introduce function into these micellar systems is
the utilization of DNA as a constituent part of the amphiphilic block
copolymer. Several ways have been established to synthesize DNA
block copolymers. Early methods to access linear DNA block copoly-
mers (DBCs) relied on coupling the ODN segment to the hydrophobic
polymer in solution which did not result in good coupling yields
[32]. A more efﬁcient approach relied on attaching the nucleic acid
segment to the DNA unit on the solid phase. Therefore, the ODN
was synthesized by conventional phosphoramidite chemistry on
controlled porous glass or a polymeric support [152]. Afterwards, a
phosphoramidite polymer, which was obtained by phosphitylation
of its terminal hydroxyl group, was coupled to the detritylated end
of the ODN that was still attached to the solid phase. After removal
of the protective groups and cleavage from the support amphiphilic
DBCs were obtained in good yields [38]. Other ways for the
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ferent enzymes [36,153–155].
After detailing their preparation methods, the self-assembly of
amphiphilic DBCs will be discussed. When these materials are intro-
duced into buffer they form spherical micelles. The size of these
nanoobjects can be easily controlled by adjusting the lengths of the
different polymer blocks. Just to give an example, a DBC consisting
of a ODN 22mer connected to a poly(propylene oxide) (PPO) segment
of weight average molecular weight (Mw) of 6800 g/mol results in
micelles with a hydrodynamic radius of 10 nm. When the DNA
block is extended to 84 nucleotides a diameter of 23 nm is obtained
[155]. The geometry of the spherical aggregates could be switched
into rod-like objects by a simple hybridization procedure [156].
Therefore, the ss DNA-b-PPO micelles were mixed with long DNA
templates that encode several times the complementary sequence
of the micelle corona inducing a transformation into rod-like micelles.
Watson–Crick base pairing aligned the hydrophobic polymer seg-
ments along the DNA double helix, which resulted in selective
dimer formation (Fig. 19). Even the length of the resulting nanostruc-
tures could be precisely adjusted by the number of nucleotides of the
templates. Rod-like particles with lengths between 30 and 37 nmwere
generated. This study demonstrated that structurally well-deﬁned DNA
nanoobjects can not only be produced by Watson–Crick base paring as
described in the context of pristine DNA assemblies but also by interac-
tions of hydrophobic polymers. The use of hydrophobic interactions
represents a new principle for DNA nanoconstruction.
The spherical and rod-like DBC nanostructures were investigated
in regard to their interaction with cells. Uptake studies into the can-
cerous Caco 2 cell line revealed an internalization behavior that is
strongly dependent on the geometry of the nanostructures [157]. It
turned out that the rod-like aggregates were taken up to a much
greater extent than ss and ds spherical micelles. In the context of
drug delivery this is an important ﬁnding because it suggests that
shape is an important design criterion for drug carriers. It is notewor-
thy that all the DNA aggregates were taken up much better than the
ss and ds DNA controls. The same ﬁnding that nanoparticles with a
high nucleic acid density are efﬁciently incorporated into cells was
previously observed for DNA-Au NPs and was later seen for pristine
DNA nanoobjects as well (vide supra).
After investigating the non-directed uptake of DBC aggregates,
these systems were employed for targeted chemotherapeutic drug
delivery [158]. For that purpose ODN-modiﬁed targeting units (folic
acid) were “clicked” into the spherical micelle corona byB
A
Fig. 19. Preparation of soft DNA nanoparticles with different shapes and the corre-
sponding AFM pictures of the nanoobjects. (A) Base pairing of ss DNA-b-PPO micelles
with a short complementary sequence yields micelles with a ds corona maintaining
the overall spherical shape of the aggregates. (B) Hybridization with long DNA tem-
plates results in rod-like micelles consisting of two parallel aligned double helices.hybridization, allowing perfect control of surface functionalities of
the nanoparticle system. When folate is conjugated to the 5′-end of
the ODN it is present at the surface of the micelles (Fig. 20A). If the
targeting moiety is connected to the 3′-end it is located at the inside
of the DBC aggregates. In addition, different stoichiometries of
ODN-folate conjugates to micelles allowed control of number of
targeting unit per micelle. The aggregation number of this DNA–b-PPO
system was determined to be 25 resulting in an average of 25 folate
units on the surface of the DBC vehicles when fully hybridized with
5′-functionlized ODNs. Cell culture experiments with Caco 2 cells re-
vealed that cellular uptake strongly depends on the density of targeting
units on the surface of the carriers. Receptor-mediated uptake is most
efﬁcient for the design with the maximum number of folate groups on
the surface. As convenient the DBC aggregates are equipped with sur-
face functionalities, as simple the drug loading can be carried out. By
just mixing the hydrophobic anticancer drug Dox with the micelles,
the cargo accumulates in the core of the DBC aggregates (Fig. 20B).
When the DBC particles that were most efﬁcient in targeting were ad-
ministered with the cytotoxic payload to cancer cells in-vitro the Caco
2 cells were efﬁciently killed, whereas the NPs themselves did not
show any toxicity.
These experiments qualify the amphiphilic DBCs as delivery system
with high future potential. The hydrophobic polymer organizes the ss
ODN moieties to form a dense ss DNA corona that can be easily
equipped with many different functionalities by hybridization as
proven for targeting and bioimaging agents. Moreover, the core of the
DNA nanoparticles can be exploited for the loading with hydrophobic
cargo. In this way a combinatorial testing of different compositions
of DBC-based drug delivery systems becomes feasible. Similarly to the
DBCmicelle system, aptamers recognizing Ramos cells were assembled
into micelles through implementation of a hydrophobic moiety at one
end of the ODN. Interestingly, due to the multimerization of the
aptamer sequence an increased binding of the micelles compared to
the pristine nucleic acid sequence was achieved [159].
In future experiments, especially during in-vivo applications, the
DBC aggregates, like any other micelle system, might disaggregate
due to dilution upon administration. For that reason we stabilized
DBC aggregates by adding a hydrophobic cross-linker to the core
that was photo-polymerized [160]. At the same time the DNA–
b-PPO system was blended with Pluronics, a triblock copolymer
with a PEG–b-PPO–b-PEG architecture. As a result, the corona of the
micelle corona consists of ODN and PEG units. It was proven that
the PEG moieties at the surface of the aggregates did not interfere
with hybridization. In this way, a stable DNA nanoparticle system
was generated combining a PEG-stealth function with all the favor-
able properties of pristine DBC micelles.
A second way of stabilizing DBC aggregates is encapsulation of the
whole nanoobject. This goal was successfully realized with virus cap-
sids. Micelles of amphiphilic DBCs acted as efﬁcient template for the
formation of virus-like particles of the Cowpea Chlorotic MottleBA
Fig. 20. Schematic representation of the drug delivery system based on DNA block co-
polymers. (A) Targeting units (red dots) that are connected to the complementary se-
quence of the micelles are hybridized to equip the nanoparticle surface with folate
moieties. (B) The anticancer drug (green dots) is loaded into the core of the micelles.
Due to hydrophobic interactions of Doxorubicin with PPO the drug accumulates in
the interior of the block copolymer aggregates.
AB
Fig. 21. DNA micelle-templated virus capsid formation. (A) Loading of hydrophobic
molecules (green) into the core. (B) Hydrophilic moieties (red) are attached to the
DNA NP by hybridization. Subsequently, coat proteins encapsulate the micelle by a
simple mixing process at neutral pH.
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self-assemble into T = 1 and T = 2 particles consisting of 90 and
120 proteins, respectively. The resulting nanoobjects exhibit a diam-
eter of approximately 20 nm. The incorporation of hydrophilic and
hydrophobic payloads was achieved in a very simple manner similar
as described earlier for the DBC drug delivery system (Fig. 21). Hydro-
phobic compounds, like pyrene, were accumulated in the core of the
micelles during preparation of DBCmicelles. Subsequently, the loaded
micelles were incorporated into CCMV particles. For the loading of
hydrophilic compounds the cargo was conjugated to complementary
ODNs to that of DBC particles prior to the encapsidation process. The
encapsulation was veriﬁed by several techniques including TEM,
FPLC, UV/Vis and ﬂuorescence spectroscopy.
While amphiphilic DBCs are superb materials for the preparation of
functionalized micelles they were also employed in the context of ves-
icle systems. DNA–b-PPOwas stably incorporated into the phospholipid
membrane of vesicles (Fig. 22) [162]. In this way, the containers are
encoded with sequence information. The ODNs present on the surface
were used for anchoring a photosensitizer by hybridization. Upon1 2
3
4
Fig. 22. Illustration of selective cargo release from DBC-decorated phospholipid vesicles.
(1) DBCs are stably anchored in unilamellar lipid vesicles; (2) DBC-decorated vesicles
are functionalized with conjugated ODN-photosensitizers by hybridization; (3) singlet
oxygen is generated by light irradiation; and (4) selective cargo release is induced by
the oxidative effect of singlet oxygen.light irradiation the PPO was oxidized leading to leakage in the mem-
brane and cargo release. It was even demonstrated that in mixtures of
vesicles payload is only released when sequence speciﬁc hybridization
takes place. Liposomes lacking the code for photo-sensitizer hybridiza-
tion remain unaffected.
When vesicles were functionalized with an aptamer recognizing
cancerous cells, targeted liposomes could be successfully delivered
[163]. In the same work the binding of the aptamer to the cell surface
could be instantaneously inhibited and disrupted by addition of the
complement of the aptamer sequence.
While in DBC micelles and DBC encoded vesicles the polymer was
employed to organize a ss DNA moiety by hydrophobic interactions
the opposite allocation of functions was realized. A DNA cube with
ss regions was employed as a scaffold to place DBCs in a predeﬁned
manner in space (Fig. 23) [164]. In this way, upon hybridization of
DBCs, synthetic polymer units could be placed at various corners of
the cube indicating that with the help of DNA nanotechnology syn-
thetic macromolecules can be programmably positioned in 3D on a
DNA scaffold. Moreover, the decoration of the cube with polymer
units increased the nuclease resistance compared to non-polymer
containing DNA cages. These hybrid structures like many of the
above mentioned DBC systems represent promising precision mate-
rials for biomedical and drug delivery applications.
4. Conclusion
DNA nanotechnology has developed into an independent ﬁeld of
research in the recent years. Dramatic improvements have been
booked regarding the accessibility of possible structures. One can
ﬁrmly state that nowadays almost any 2D or 3D shaped nanoobject
is achievable with DNA as a building block. In contrast to many
other self-assembling systems the geometry and size of DNA
nanoarchitectures can be designed very accurately due to the
well-known self-recognition properties of DNA and the knowledge
of the exact structure of the double helix on the atomic level. Without
any doubt, the DNA origami technique is nowadays the one giving the
highest degree of ﬂexibility regarding the structural variety. Although
DNA nanostructures being composed of nucleic acid hybrid materials
allow less structural control and variability they give the opportunity
for the implementation of extra functionality.
Both types of materials, pristine DNA nanoobjects and DNA hybrid
structures, were exploited in the context of biomedical applications.
DNA nanoobjects were employed as scaffolds to act as a drug carrier
or to display functionalities that induce immunostimulation. Why
are nucleic acid nanostructures so appealing for those potential appli-
cations? There are several answers to this question. One obvious oneDNA
ROMP
Polymer
Fig. 23. Schematic design of a polymer-conjugated DNA cube. The cube is designed to
hybridize with four DNA polymer conjugates, two on both the top and bottom face. In
each face the polymers are directed perpendicular to each other through site-speciﬁc
hybridization in order to minimize steric hindrance.
Reproduced with permission from [163].
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functionalities including drugs, targeting moieties and stealth units.
With the help of the DNA scaffold these entities can be positioned
with a similar accuracy as the DNA itself. The great need for
multifunctional carriers in the context of drug delivery vehicles does
not need to be further explained here. Another striking feature of the
DNA nanoobjects is their modular fabrication relying on self-assembly.
Only a few or a large number of building blocks are mixed together in
a single step resulting in the formation of the desired nanostructure.
In this way, variations of the design or the decoration of the carrier
can be easily achieved. In stark contrast, other carrier scaffolds like
dendrimers mostly require cumbersome multistep synthesis which
does not allow testing of many designs and structural variations. It
needs to bementioned here that the DNA sequences need to be synthe-
sized as well, but their fabrication relies on well-established automated
synthesis methods and ODNs are available from commercial suppliers.
Moreover, via the self-assembly process with DNA a large size range is
covered ranging from only a few nanometer like the DNA tetrahedron
to structures in the micrometer scale like the extended DNA tubes. An-
other striking feature suggesting the use of DNA-based carrier systems
is that they are taken up by cells without the need for a transfection
agent. This was ﬁrst discovered for DNA-Au NPs and seems to be true
for many other DNA nanostructures as well that are composed of high
density DNA like DBC micelles, DNA polyhedra and DNA origami
tubes. An equally important characteristic for their biomedical applica-
tion is their low immunogenicity. Several examples in this review dem-
onstrate that once the DNA is tightly compressed in a dense DNA
scaffold immunogenicity is low like shown for some pristine DNA and
DNA-Au NPs. Moreover, for all DNA-based materials presented in this
reviewno or only a low toxicitywas found in the absence of the payload
or stimulants, while they greatly improve the performance of the active
compounds.
While DNA nanostructures from pristine nucleic acids and from
DNA hybrid material have several common features they also exhibit
differences. Pristine DNA nanostructures mostly allow more structur-
al control if one thinks e.g. of the DNA origami method compared to
DNA-Au NPs or DBC micelles. On the other hand DNA-Au NPs and
DBC aggregates allow much higher densities of surface units com-
pared to pristine nucleic acid structures. For the former ones ss DNA
is arranged in space by an Au- or a hydrophobic polymer core while
for the latter ones overhangs of ss DNA can be introduced into double
helical structures with lower frequency.
Another good reason for testingDNAnanostructures for the purpose
of drug delivery is the large ﬂexibility of how drugs can be loaded into
the DNA carrier. As demonstrated for chemotherapeutics like Dox inter-
calation into the double helix is a valuablemethod. But drugs can also be
chemically attached to the surface of the nanocarriers which at the
same timehelps increasing the solubility of a drug. Alternatively, hydro-
phobic actives might be incorporated into the lipophilic core of DBCTable 1
Overview of DNA nanostructures equipped with CpG motifs for immunostimulation.
Class DNA nanoobject Reference Immunostimulatory effect
Pristine DNA Tetrahedron [59] Tetrahedra functionalized with 4 CpG m
compared to ds CpG motifs.
[60] Doubled antibody response and signiﬁc
vaccines compared to the unassembled
Dendrimers [64] Y shaped structures cause a 1.5- to 3-fo
[65] 2nd and 3rd dendrimer generations str
IL-6 concentrations were approx. incre
Polypods [66] With increasing branching of the pods
5-fold to 400-fold increase was observe
detection limit.
DNA tubes [52] TLR9 speciﬁc immune responses were tr
compared to undecorated tubes.
DNA hybrids DNA-Au NPs [130] Strongly stimulated cytokine release in
in TNF-α and IL-6 concentrations wasaggregates. Another loading strategy consists of hybridizing drug-ODN
conjugates onto single stranded sites of the DNA carrier.
While DNA nanoobjects offer several possibilities for drug incor-
poration they allow superb control over release as well. Due to the
speciﬁc hydrogen bonds formed between adenine and thymine and
guanosine and cytosine the melting temperature between two com-
plementary DNA strands can be precisely controlled. This feature
can be exploited for the temperature-controlled release of com-
pounds that are attached to the strands or that are intercalated. Like-
wise, the hydrogen bonding in DNA can be exploited for sequence
speciﬁc release with the help of DNA or RNA input strands. In this
case one of the strands needs to contain a toehold overhang that al-
lows strand exchange and therewith release. Other DNA-mediated re-
lease mechanisms rely on speciﬁc DNA sequences. The i-motif is
switching in response to pH between a compact quadruplex structure
and an extended single stranded conformation. This allowed con-
trolled release when those structures are introduced as valves at the
tip of silica channels. Light as a stimulus for drug release is another
option. In case of silica particles a photobase induces local pH changes
and switching of the i-motif. On the surface of liposomes photosensi-
tizer units can be hybridized and exploited for sequence-speciﬁc re-
lease of cargo.
The summary above shows that pristine DNA nanostructures and
nanoobjects composed of DNA hybrid materials offer unprecedented
control over structure and functionality in a biological or cellular en-
vironment. Several in-vitro studies have shown the exciting proper-
ties of nano-sized nucleic acid-based carrier materials. However, the
scope of these investigations is still limited. The focus has been on
two main areas, i.e. usage of DNA-based carriers for cancer treatment
and as immunostimulants exploiting the multimerization of the CpG
motif (Table 1). Further in-vitro experiments might extend the appli-
cations of this carrier family to other indications and diseases. Even
more important for the demonstration of the great potency of DNA
nanomaterials in the biomedicine arena is the establishment of
these vehicles in-vivo. Such experiments are still scarce but one can
imagine that more successful examples will be presented soon due
to the fact that the ﬁeld of DNA-based carriers has gained great mo-
mentum in the very recent years. In the near future it is expected
that the scope and limitations of such delivery vehicles regarding in-
dications, targeting-ability, toxicity, immunogenicity, pharmacoki-
netics and pharmacological efﬁcacy (local pharmacological effects,
toxicity in non-target tissue, and overall effect on disease progres-
sion) will be shown. This preclinical validation calls for fabrication
of DNA nanomaterials of pharmaceutical grade and at larger scales.
For pristine nucleic acids and DNA block copolymers these require-
ments can be met with established techniques such as solid-phase
synthesis and automated HPLC. One example thereof is the commer-
cially available anti-VEGF nucleic acid aptamer used for treatment of
wet age related macular degeneration [30]. In regard to inorganicotifs increase TNF-α and IL-6 concentrations by a factor of 13 and 35, respectively,
antly higher levels of memory B cells were found when using the NP enhanced
individual components.
ld increase in release of TNF-α and IL-6, respectively, compared to ds CpG.
ongly increase TNF-α levels by a factor of 7 and 22, respectively, compared to ds CpG.
ased by a factor of 3 (G2) and 5 (G3).
an enhanced stimulation was found for both TNF-α and IL-6. For the prior cytokine a
d compared to ds DNA. For IL-6 release induced by ds DNA the values were below the
iggered using CpG decorated nanotubes with a ﬁvefold increase in IL-6 concentrations
comparison with non-NP CpG motifs. In relation to ss CpG, a 16- and 10-fold increase
observed, respectively.
481J.W. de Vries et al. / Journal of Controlled Release 172 (2013) 467–483DNA hybrids, probably more effort is necessary to achieve the homo-
geneity and scale established in pharmaceutical industry. These
considerations help to realize the long-term goal of this branch of
nanomedicine research which is to identify promising nucleic
acid-based carrier systems and bring them into the clinic. However,
the latter endeavor is beyond a short time frame.References
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